Arcturus Therapeutics Holdings Inc is a biotechnology company focused on the development of transformative RNA medicines. The company utilizes its proprietary platform to create innovative therapies targeting various diseases, including infectious diseases and genetic disorders. By leveraging advanced technologies, such as self-amplifying mRNA and lipid nanoparticle delivery systems, Arcturus aims to improve the efficacy and safety of vaccines and therapeutics. Their pipeline includes candidates designed for both human and veterinary applications, reflecting their commitment to addressing significant unmet medical needs and enhancing patient outcomes. Read More
NetworkNewsWire Editorial Coverage : Innovation in RNA-based, immunotherapy and targeted therapeutics is not just aspirational, it’s urgently needed. Aggressive cancers such as glioblastoma and pancreatic cancer remain devastatingly lethal, while pediatric rare diseases continue to claim too many young lives each year. In this landscape of unmet medical need, Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ) stands out. Under the visionary leadership of chair and CEO Dr. Vuong Trieu, the company is leveraging AI, nanomedicine and novel clinical models to reshape biotech. With a robust IP backbone, bolstered by more than 500 patent applications and 75 issued patents, Oncotelic is building a breakthrough portfolio aimed at transforming cancer and rare disease treatment. The company is joining other leading innovators in the cancer and rare disease treatment space, including IO Biotech Inc. (NASDAQ: IOBT), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Autolus Therapeutics PLC (NASDAQ: AUTL) and…
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that the Company will participate in the following investor conferences:
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the second quarter ended June 30, 2025, and provided corporate updates.
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2025 after the market close on Monday, August 11 and will also host a conference call and webcast at 4:30 pm Eastern Time on August 11, 2025.
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announces positive Phase 2 interim results in people with OTC deficiency treated with ARCT-810, an mRNA therapeutic candidate designed to replace the OTC enzyme and restore urea cycle activity preventing hyperammonemia crises.
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will host a virtual KOL presentation of ARCT-810 Phase 2 interim data for Ornithine Transcarbamylase (OTC) deficiency on Monday, June 30, 2025, at 12:00 p.m. ET. The Company will issue a press release summarizing the data at 11 am ET, prior to the presentation.
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences:
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corporate updates.
